Zobrazeno 1 - 9
of 9
pro vyhledávání: '"Girolamo Pelaia"'
Autor:
Gianenrico Senna, Maria Aliani, Elena Altieri, Pietro Bracciale, Luisa Brussino, Maria Filomena Caiaffa, Paolo Cameli, Giorgio Walter Canonica, Cristiano Caruso, Maria D'Amato, Fausto De Michele, Stefano Del Giacco, Fabiano Di Marco, Francesco Menzella, Girolamo Pelaia, Paola Rogliani, Micaela Romagnoli, Pietro Schino, Jan Walter Schroeder, Alessandra Vultaggio, Sara Rizzoli, Alessandro Zullo, Silvia Boarino, Marilena Palmisano, Alessandra Rossi, Gianfranco Vitiello, Stefano Centanni
Publikováno v:
Journal of Asthma and Allergy. 15:1593-1604
Gianenrico Senna,1,2 Maria Aliani,3 Elena Altieri,4 Pietro Bracciale,5 Luisa Brussino,6 Maria Filomena Caiaffa,7 Paolo Cameli,8 Giorgio Walter Canonica,9,10 Cristiano Caruso,11 Maria DâAmato,12 Fausto De Michele,13 Stefano Del Giacco,14 Fabiano
Publikováno v:
Expert Opinion on Pharmacotherapy. 21:1505-1515
'Critical Asthma Syndrome' (CAS) is an umbrella term proposed to include several forms of asthma, responsible for acute and life-threatening exacerbations. CAS requires urgent and adequate supportive and pharmacological treatments to prevent serious
Autor:
Claudia Crimi, Luca Gallelli, Corrado Pelaia, Alessandro Vatrella, Rosa Terracciano, Girolamo Pelaia
Publikováno v:
Expert Review of Respiratory Medicine. 14:501-510
Introduction: Mitogen-activated protein kinases (MAPKs) are a large family of evolutionary conserved intracellular enzymes that play a pivotal role in signaling pathways mediating the biologic actions of a wide array of extracellular stimuli.Areas co
Autor:
Nicola Scichilone, Vittorio Cardaci, Mauro Carone, Pietro Pirina, Patrizio Pasqualetti, Piero Balbo, Alessandro Vatrella, Girolamo Pelaia, Nunzio Crimi, Pierachille Santus, Pietro Roversi, Giuseppe Girbino, Fabiano Di Marco, Francesco De Blasio
Publikováno v:
International Journal of Chronic Obstructive Pulmonary Disease. 14:353-360
Purpose There is a lack of consensus on the most appropriate early diagnostic strategy, criteria for early access to treatment and follow-up approach for patients with COPD. Materials and methods A Delphi consensus project investigated the early mana
Autor:
Rocco Savino, Rosa Terracciano, Paolo Navalesi, Alessandro Vatrella, Girolamo Pelaia, Nicola Lombardo, Corrado Pelaia
Publikováno v:
Expert Opinion on Biological Therapy. 18:197-204
Allergen-specific immunotherapy (AIT) is indicated for patients with allergic asthma and/or allergic rhinitis, and can be implemented by either subcutaneous injection (SCIT) or sublingual administration (SLIT). AIT reduces asthma symptoms, lowers the
Autor:
Rocco Savino, Corrado Pelaia, Rosa Terracciano, Alessandro Vatrella, Maria Teresa Busceti, Girolamo Pelaia, Luca Gallelli
Publikováno v:
Drug Design, Development and Therapy
Mepolizumab is an anti-interleukin-5 (IL-5) humanized monoclonal antibody that has been recently approved as an add-on biological treatment for severe eosinophilic asthma, by both the US Food and Drug Administration (FDA) and the European Medicines A
Autor:
Nicola Lombardo, Mariaimmacolata Preianò, Rosa Terracciano, Girolamo Pelaia, Maria Teresa Busceti, Alessandro Vatrella, Rosario Maselli, Luca Gallelli
Publikováno v:
Therapeutics and Clinical Risk Management
Within the context of the heterogeneous phenotypic stratification of asthmatic population, many patients are characterized by moderate-to-severe eosinophilic asthma, not adequately controlled by relatively high dosages of inhaled and even oral cortic
Autor:
Luca Gallelli, Serafino A. Marsico, Girolamo Pelaia, Alessandro Vatrella, Rosario Maselli, Teresa Renda, Mario Caputi
Publikováno v:
International Journal of Chronic Obstructive Pulmonary Disease
COPD is a widespread inflammatory respiratory disorder characterized by a progressive, poorly reversible airflow limitation. Currently available therapies are mostly based on those used to treat asthma. However, such compounds are not able to effecti
Autor:
Maria Teresa Busceti, Alessandro Vatrella, Serafino A. Marsico, Luca Gallelli, Rosa Daniela Grembiale, Girolamo Pelaia, Rosario Maselli, Pasquale Romeo, Teresa Renda
Publikováno v:
Journal of Asthma and Allergy
Omalizumab is a humanized monoclonal anti-IgE antibody recently approved for the treatment of severe allergic asthma. This drug inhibits allergic responses by binding to serum IgE, thus preventing interaction with cellular IgE receptors. Omalizumab i